- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.09. | ME Therapeutics Holdings Inc: ME Therapeutics begins testing on mRNA formulations | 4 | Stockwatch | ||
| 18.09. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces the Start of Testing of First mRNA Formulations from NanoVation Therapeutics Collaboration | 170 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - September 18, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 08.07. | ME Therapeutics to collaborate with NanoVation Therapeutics | 1 | The Market Herald Canada | ||
| 08.07. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces New Collaboration with NanoVation Therapeutics on Advanced Therapeutic mRNA Delivery to Myeloid Cells | 323 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 8, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 29.05. | ME Therapeutics Holdings Inc: ME Therapeutics appoints two consultants | 1 | Stockwatch | ||
| 29.05. | ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial | 154 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 17.05. | ME Therapeutics Holdings Inc.: ME Therapeutics to Present at Investor Clubhouse at the Canadian Open and Attend the 2024 BIO International Convention for Partnering Opportunities | 288 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working... ► Artikel lesen | |
| 15.04. | ME Therapeutics Holdings Inc. Announces Ringing of CSE Opening Bell on April 17, 2024 | 220 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs... ► Artikel lesen | |
| 09.04. | ME Therapeutics Holdings Inc: ME Therapeutics grants option to buy 250,000 shares | 1 | Stockwatch | ||
| 26.03. | ME Therapeutics Holdings Inc. Announces Upcoming Participation in the 2024 Bloom Burton & Co Health Care Conference and Interview On CSE TV | 156 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T), a preclinical stage biotechnology company working on novel cancer fighting drugs... ► Artikel lesen | |
| 06.03. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces Closing of Non-Brokered Private Placement | 207 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - March 6, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 27.02. | ME Therapeutics Holdings Inc.: ME Therapeutics Announces Non-Brokered Private Placement and Provides Corporate Update | 505 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company... ► Artikel lesen | |
| 11.12.23 | ME Therapeutics Holdings Inc. Announces Listing on the Frankfurt Stock Exchange (FSE) and the Completion of Its Redesigned Website | 323 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 11, 2023) - ME Therapeutics Holdings Inc. (CSE: METX), a preclinical stage biotechnology company working on novel cancer fighting drugs in the... ► Artikel lesen | |
| 11.12.23 | XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 11.12.2023 | 1.081 | Xetra Newsboard | The following instruments on XETRA do have their first trading 11.12.2023 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 11.12.2023
Aktien
1 CA5527671054 Me Therapeutics Holdings... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 39,400 | -0,63 % | Wieder eine Aktie im Konsolidierungsdreieck gefangen - QIAGEN! | ||
| NUVALENT | 104,93 | +1,38 % | Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) CFO Sells 10,000 Shares of Stock | ||
| DYNE THERAPEUTICS | 32,580 | -2,75 % | Peering Into Dyne Therapeutics' Recent Short Interest | ||
| SUMMIT THERAPEUTICS | 19,090 | +2,58 % | Summit Therapeutics Aktie: Kurseinbruch trotz positiver Jahresentwicklung | ||
| LONGBOARD PHARMACEUTICALS | 36,220 | +0,47 % | Longboard Pharmaceuticals gains amid takeover speculation | ||
| CG ONCOLOGY | 36,630 | +1,95 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| IMMUNOVANT | 30,510 | +4,20 % | Zacks Research Comments on Immunovant, Inc.'s FY2026 Earnings (NASDAQ:IMVT) | ||
| BIONTECH | 111,80 | 0,00 % | BioNTech vs. Moderna: Spannendes Duell auf Augenhöhe | Die beiden Impfstoffunternehmen lieferten sich schon während der Coronazeit ein hartes Kopf-an-Kopf-Rennen. Nun wird es spannend, wer in den kommenden Jahren die Nase vorn haben wird.Es war am 11. März... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 34,600 | -0,49 % | Mizuho erweitert Liste der Top Picks: Harmony Biosciences und Fortive neu dabei | ||
| RECURSION PHARMACEUTICALS | 6,110 | +0,83 % | Recursion Pharmaceuticals, Inc.: Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma | First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing of Phase... ► Artikel lesen | |
| EVOTEC | 6,140 | +2,50 % | Aktien KW 39 - Rekordjagd. Weiter so? 20.000 im DAX denkbar? News. Mutares. Salzgitter. Energiekontor. SMA Solar. Evotec. Novo Nordisk. The Platform Group | Aktien Wochenrückblick - die Märkte setzen auf das Ende der Inflation. Basis des aktuellen Aufschwungs legte die EZB mit ihrem Zinsschritt, dann folgte letzte Woche die FED mit einem "grossen" Zinsschritt... ► Artikel lesen | |
| JANUX THERAPEUTICS | 45,020 | +1,92 % | Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen | |
| ADMA BIOLOGICS | 20,265 | +3,55 % | ADMA Biologics stock soars to all-time high of $20.16 | ||
| COGENT BIOSCIENCES | 11,110 | +5,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results | SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund... ► Artikel lesen | |
| DISC MEDICINE | 49,930 | -0,44 % | Disc Medicine Inc: Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update | Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and... ► Artikel lesen |
Das Unternehmen ME THERAPEUTICS HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,180 Euro und damit +0,93 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ME THERAPEUTICS HOLDINGS INC finden Sie auf Wallstreet Online.
